Intuitive Surgical outlook in focus, consensus points to robust earnings growth

Analyst estimates for Intuitive Surgical point to mid?teens earnings growth into 2026, while recent commentary highlights both higher da Vinci procedure guidance and a valuation still above the sector average.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 08:17.

Intuitive Surgical (US46120E6023) draws sustained analyst attention on NASDAQ as investors reassess its medium-term earnings power. Recent estimates for 2026 imply mid-teens earnings growth alongside higher procedure guidance for the da Vinci system, according to Zacks and other data providers. Zacks analysis of Intuitive Surgical's outlook

What current estimates signal

Zacks reports that the consensus estimate for Intuitive Surgical's 2026 earnings implies a 16.6% increase versus the prior-year period, underscoring expectations for continued growth in robotic-assisted procedures. Zacks consensus figures cited by Nasdaq The stock is currently rated Zacks Rank #2 (Buy), indicating a favorable risk-reward profile in that framework.

On a valuation basis, Zacks highlights a forward price-to-earnings multiple of 36.55 times for Intuitive Surgical, above the broader medical sector’s average but meaningfully below the company's five-year median of 70.02 times. Zacks valuation comparison The research house assigns the shares a Value Score of D, reflecting a premium valuation despite the recent share-price pullback.

Procedure growth and guidance

In its first-quarter 2026 communication, Intuitive Surgical's management raised its 2026 da Vinci procedure growth guidance to a range of 13.5% to 15.5%, up from the previous 13% to 15% band, citing a broadly diversified procedure growth profile across regions and specialties. Q1 commentary on da Vinci guidance This suggests that higher utilization of installed systems is expected to be a central driver of revenue expansion.

Zacks notes that Intuitive Surgical's shares have declined 28.9% year to date compared with an 18.2% drop for its broader medical instruments industry group, despite this upgraded outlook. Sector underperformance data The divergence between operating momentum and share-price performance is a key theme in current analyst discussion.

How Intuitive Surgical makes its money

Intuitive Surgical generates revenue primarily from the da Vinci robotic-assisted surgery ecosystem, which combines capital sales of surgical systems, recurring instrument and accessory sales, and service contracts for installed systems. Company description of the business model Each procedure performed on a da Vinci system consumes proprietary instruments, making procedure growth a central earnings lever.

Where the shares trade today

Intuitive Surgical shares (US46120E6023) last closed on 2026-06-23 on NASDAQ at 403.18 US dollars, corresponding to an aftermarket indication of 403.00 US dollars at 19:58 Eastern Time, according to recent quote data. MarketBeat price snapshot for ISRG

Key data on the Intuitive Surgical shares

• Company: Intuitive Surgical, Inc.
• ISIN: US46120E6023
• WKN: 888024
• Ticker: ISRG
• Trading venue: NASDAQ
• Price (as of 2026-06-23, 19:58): 403.00 USD
• Market cap: 142.71 billion USD (as of 2026-06-23)
• Sector / industry: Health Care / Medical Instruments & Supplies
• Index membership: NASDAQ-100, S&P 500
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an invitation to buy or sell securities. Investors should conduct their own research and consider their individual financial situation before making investment decisions.